Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377550 | 1.00 | KDM4E (0.42) | KDM4ESMN1; SMN2ADRA2AADRA2BADRA2C | |
| SCHEMBL29478590 | 0.96 | SMN1; SMN2 (0.46) | KDM4ESMN1; SMN2ADRA2AADRA2BADRA2C | |
| SCHEMBL6026284 | 0.96 | SMN1; SMN2 (0.46) | KDM4ESMN1; SMN2ADRA2AADRA2BADRA2C | |
| SCHEMBL27202528 | 0.94 | SMN1; SMN2 (0.45) | KDM4ESMN1; SMN2ADRA2AADRA2BADRA2C | |
| SCHEMBL17868735 | 0.77 | ADRA2A (0.44) | KDM4ESMN1; SMN2ADRA2AADRA2BADRA2C | |
| SCHEMBL28614325 | 0.77 | PNMT (0.53) | ADRA2AADRA2BADRA2CHTTGRM5 | |
| SCHEMBL29478566 | 0.77 | PNMT (0.53) | ADRA2AADRA2BADRA2CHTTGRM5 | |
| SCHEMBL3407126 | 0.77 | PNMT (0.53) | SMN1; SMN2ADRA2AADRA2BADRA2CHTT | |
| SCHEMBL12273215 | 0.75 | CYP11B2 (0.41) | HTTCYP11B2CYP19A1CYP11B1GRM5 | |
| SCHEMBL846335 | 0.75 | MAP3K14 (0.35) | KDM4EHTTALDH1A1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA KIRIN CO LTD (JP) | 2020-08-06 | — | — | US | disclosed |
| US-10407440-B2 | Therapeutic agent for motor disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-09-10 | — | — | US | disclosed |
| EP-3378860-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-09-26 | — | — | EP | disclosed |
| EP-2433938-B1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-20170275296-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA KIRIN CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-9714257-B2 | Therapeutic agent for motor disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-07-25 | — | — | US | disclosed |
| EP-2474544-B1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-12 | — | — | EP | disclosed |
| EP-2474543-B1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-05-03 | — | — | EP | disclosed |
| US-9249135-B2 | Therapeutic agent for mood disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20150225417-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA KIRIN CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2474544-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| EP-2474543-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| CN-102482272-A | Therapeutic agent for mood disorders | KYOWA HAKKO KIRIN CO LTD | 2012-05-30 | — | — | CN | disclosed |
| US-20120101101-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-2433938-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | TPH1, HDAC1, HDAC2 | KDM4E 2195/4885SMN1; SMN2 4025/4885ADRA2A 450/4885 |
| US-10407440-B2 | Therapeutic agent for motor disorders | DDT, COMT, SLC6A3 | KDM4E 4721/4885SMN1; SMN2 81/4885ADRA2A 483/4885 |
| US-20170275296-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | KDM4E 4721/4885SMN1; SMN2 81/4885ADRA2A 483/4885 |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | KDM4E 3799/4885SMN1; SMN2 3241/4885ADRA2A 48/4885 |
| US-20120101101-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | KDM4E 4721/4885SMN1; SMN2 81/4885ADRA2A 483/4885 |
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | KDM4E 3799/4885SMN1; SMN2 3241/4885ADRA2A 48/4885 |
| US-20150225417-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | KDM4E 4721/4885SMN1; SMN2 81/4885ADRA2A 483/4885 |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN2 | KDM4E 1732/4885SMN1; SMN2 967/4885ADRA2A 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.